SCHEMBL2215780

SCHEMBL2215780

OCc1ccn(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.62

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.62
UBE2N P61088 1/20 0.44
CASR P41180 5/20 0.44
KCNH2 Q12809 2/20 0.41
SRC P12931 1/20 0.40
BRAF P15056 1/20 0.40
KDR P35968 1/20 0.40
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
AR P10275 3/20 0.37
AADAT Q8N5Z0 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31273314 0.85 NOTUM (0.45) NOTUMUBE2NCASRKCNH2SRC
SCHEMBL17887295 0.81 NOTUM (0.42) NOTUMUBE2NCASRKCNH2NPC1
SCHEMBL508718 0.79 RXRA (0.44) NOTUMMAPTPOLB
SCHEMBL28835086 0.79 UBE2N (0.46) NOTUMUBE2NCASRKCNH2SRC
SCHEMBL26970950 0.78 MAOA (0.41) NOTUMCASRMAPT
SCHEMBL15670374 0.78 NOTUM (0.42) NOTUMNPC1MAPTRAB9APOLB
SCHEMBL5904887 0.77 NOTUM (1.00) NOTUMKCNH2MAPT
SCHEMBL30999699 0.77 NPC1 (0.54) NOTUMUBE2NCASRSRCBRAF
SCHEMBL16322113 0.77 NOTUM (0.59) NOTUMUBE2NKCNH2NPC1MAPT
SCHEMBL12438819 0.77 NOTUM (0.59) NOTUMUBE2NCASRNPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4722208-A1 NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Samjin Pharmaceutical Co., Ltd. (KR) 2026-04-08 EP disclosed
WO-2024246764-A1 NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 삼진제약주식회사 2024-12-05 WO disclosed
EP-2212284-B1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC (US) 2014-04-30 EP disclosed
EP-2212284-B1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC (US) 2014-04-30 EP disclosed
US-8334317-B2 Calcium receptor modulating agents AMGEN INC. (US) 2012-12-18 US disclosed
US-8334317-B2 Calcium receptor modulating agents AMGEN INC. (US) 2012-12-18 US disclosed
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-07-21 US disclosed
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-07-21 US disclosed
WO-2009051718-A2 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178133-A1 CALCIUM RECEPTOR MODULATING AGENTS CASR, CALCR, RYR1 NOTUM 4419/4885UBE2N 4353/4885CASR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.